ZFIN ID: ZDB-FISH-150901-21362
Fish name: gl22Tg
Genotype: gl22Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by gl22Tg
Human Disease Conditions Citations
cancer cancer xenotransplantation Hamilton et al., 2016
glioblastoma cancer xenotransplantation Hamilton et al., 2016
GENE EXPRESSION
Gene expression in gl22Tg
RNA expression
Expressed Gene Structure Conditions Figures
apoeb control Fig. 3 from Mazzolini et al., 2019
cdx1b control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
csf1ra control Fig. 3 from Mazzolini et al., 2019
Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
foxq1a standard conditions Fig. 2 with image from Earley et al., 2018
foxq1b standard conditions Fig. 2 with image from Earley et al., 2018
gbp4 control Fig. 1 from Tyrkalska et al., 2016
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
hexb control Fig. 3 from Mazzolini et al., 2019
htr2b standard conditions Fig. 3 with image from Yang et al., 2017
il1b control Fig. 1 from Tyrkalska et al., 2016
bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
irf8 control Fig. 3 from Mazzolini et al., 2019
mpeg1.1 control Fig. 3 from Mazzolini et al., 2019
mpx control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
npsn control Fig. 1 with image from Di et al., 2017
p2ry12 control Fig. 3 from Mazzolini et al., 2019
plxnb2a.1 control Fig. 3 from Mazzolini et al., 2019
caiap bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 3 from Tyrkalska et al., 2017
spi1b control Fig. 3 from Mazzolini et al., 2019
tnfa standard conditions Fig. 7 from Espín-Palazón et al., 2014
trim9 control Fig. 2 from Tokarz et al., 2017
chemical treatment by environment: N-palmitoyl-S-[2,3-bis(palmitoyloxy)propyl]-Cys-Ser-Lys-Lys-Lys-Lys Fig. 2 from Tokarz et al., 2017
vegfaa control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
vegfc control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
vegfd control Fig. 3 with image from Okuda et al., 2015
chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 3 with image from Okuda et al., 2015
PHENOTYPE
Phenotype in gl22Tg
Phenotype Conditions Figures
fatty acid transport process quality, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 8 from Hall et al., 2014
gall bladder morphology, abnormal chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
head macrophage increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 5Fig. 8 from Hall et al., 2014
head macrophage increased amount, abnormal high fat Fig. 8 with image from Misselbeck et al., 2019
head macrophage increased amount, ameliorated bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium, chemical treatment: PPARalpha agonist Fig. 8 from Hall et al., 2014
head macrophage normal amount, ameliorated high fat, chemical treatment by environment: ibrutinib Fig. 9 with image from Misselbeck et al., 2019
intestine macrophage amount, ameliorated chemical treatment: 2,4,6-trinitrobenzenesulfonic acid, chemical treatment: mesalamine Fig. 2 with image from Okuda et al., 2015
intestine macrophage increased amount, abnormal chemical treatment: 2,4,6-trinitrobenzenesulfonic acid Fig. 2 with image from Okuda et al., 2015
macrophage accumulation liver and biliary system, abnormal chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
macrophage EGFP expression decreased amount, abnormal chemical treatment by injection: monosodium urate Fig. 6 from Hall et al., 2018
macrophage caiap expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 3 from Tyrkalska et al., 2017
macrophage il1b expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
macrophage EGFP expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
macrophage trim9 expression increased amount, abnormal chemical treatment by environment: N-palmitoyl-S-[2,3-bis(palmitoyloxy)propyl]-Cys-Ser-Lys-Lys-Lys-Lys Fig. 2 from Tokarz et al., 2017
macrophage trim9 expression increased amount, abnormal chemical treatment by environment: poly(I:C) Fig. 2 from Tokarz et al., 2017
macrophage reactive oxygen species biosynthetic process increased occurrence, abnormal chemical treatment by injection: monosodium urate Fig. 6 from Hall et al., 2018
male organism macrophage htr2b expression increased amount, abnormal standard conditions Fig. 3 with image from Yang et al., 2017
neutrophil accumulation liver and biliary system, abnormal chemical treatment: biliatresone Fig. 3 from Lorent et al., 2015
reactive oxygen species biosynthetic process decreased occurrence, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium, chemical treatment: PPARalpha agonist Fig. 6 with image from Hall et al., 2013
regenerating tissue macrophage decreased amount, abnormal transection: spinal cord, chemical treatment by environment: dexamethasone Fig. 1 from Tsarouchas et al., 2018
regenerating tissue macrophage increased amount, abnormal transection: spinal cord, chemical treatment by environment: lipopolysaccharide Fig. 1 from Tsarouchas et al., 2018
whole organism il1b expression increased amount, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 1 from Tyrkalska et al., 2016
whole organism macrophage amount, ameliorated high cholesterol, chemical treatment by environment: ibrutinib Fig. S12 from Misselbeck et al., 2019
whole organism macrophage increased amount, abnormal high cholesterol Fig. 8 with image from Misselbeck et al., 2019
yolk macrophage increased amount, abnormal high fat Fig. 8 with image from Misselbeck et al., 2019
yolk macrophage normal amount, ameliorated high fat, chemical treatment by environment: ibrutinib Fig. 9 with image from Misselbeck et al., 2019

CITATIONS  (50)